ONCOMED PHARMACEUTICALS RAISES $13.9 MILLION IN SERIES A FINANCING

OncoMed Pharmaceuticals, a company pioneering the development of novel therapeutics that target recently characterized self-renewing cancer cells, or "cancer stem cells", today announced the completion of a Series A preferred stock financing totaling $13.9 million. OncoMed investors include top-tier venture capital firms Latterell Venture Partners, US Venture Partners (USVP), Morgenthaler Ventures and The Vertical Group.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-07-2005/0004101668&EDATE=)